Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) and Eisai’s (TYO: 4523) Lenvima (lenvatinib mesylate) have clocked up two notable milestones.
They are the first combination of an anti-PD-1 therapy and a kinase inhibitor to be approved for advanced endometrial carcinoma in the USA, in what is also a pioneering approval for another reason.
The combination is also the first approval under a new program initiated by the US Food and Drug Administration (FDA) which has meant simultaneous review decisions in the USA, Canada and Australia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze